Abstracts tagged "Cognitive dysfunction"

Abstract Number: 0777 • ACR Convergence 2021
Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
Santiago Arciniegas¹, Sarah Mossad², Tala El Tal³, Lawrence Ng⁴, Paris Moaf⁴, Helen Branson⁴, Adrienne Davis⁴, Linda Hiraki⁴, Deborah Levy⁴, Ashley Danguecan² and Andrea Knight², ¹University of Toronto/The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive complaints are common in children with childhood-onset systemic lupus erythematosus (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase…
Abstract Number: 0859 • ACR Convergence 2021
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) affects approximately 40% of SLE patients (1), impacting on employment, daily function, and quality of life (2)(3). Diagnostic neuropsychological testing is…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Sebastian Sattui¹, Iris Navarro-Millan², Fenglong Xie³, Mangala Rajan², Huifeng Yun⁴ and Jeffrey R Curtis⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
Abstract Number: 1260 • ACR Convergence 2020
Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Kathleen Bingham¹, Juan Pablo Diaz-Martinez², Mahta Kakvan², Robin Green³, Dorcas Beaton⁴, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Denisse Bonilla⁸, Nicole Anderson², Joan Wither², Patricia Katz⁹ and Zahi Touma¹⁰, ¹Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University Health Network, Toronto, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a consistent relationship between cognition and depression and anxiety (affective symptoms) in lupus. Together, affective and cognitive symptoms represent among lupus’ most…
Abstract Number: 1268 • ACR Convergence 2020
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
Bahar Moghaddam¹, Robin Green², Dorcas Beaton³, Kathleen Bingham⁴, Mahta Kakvan⁵, Lesley Ruttan², Carmela Tartaglia⁶, Marvin Fritzler⁷, May Choi⁸, Jiandong Su⁵, Juan Pablo Diaz-Martinez⁵, Dennisse Bonilla⁵, Nicole Anderson⁵, Joan Wither⁵, Patricia Katz⁹ and Zahi Touma¹, ¹University of Toronto, toronto, ON, Canada, ²Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ³Institute for Work & Health, Toronto, ON, Canada, ⁴Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to neuropsychiatric manifestations including cognitive impairment (CI). The gold standard for assessment of SLE cognitive function is the…
Abstract Number: 1276 • ACR Convergence 2020
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Kimberley Yuen¹, Dorcas Beaton², Kathleen Bingham³, Jiandong Su⁴, Mahta Kakvan⁴, Juan Pablo Diaz-Martinez⁴, Carmela Tartaglia⁵, Lesley Ruttan⁶, Joan Wither⁴, Nicole Anderson⁴, Dennisse Bonilla⁴, May Choi⁷, Marvin Fritzler⁸, Patricia Katz⁹, Robin Green⁶ and Zahi Touma¹⁰, ¹Queen's University School of Medicine; University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is common in systemic lupus erythematosus (SLE) patients, however there is no standard screening tool available. The American College of Rheumatology…
Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Juan Pablo Diaz-Martinez¹, Kathleen Bingham², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan¹, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su¹, Dennisse Bonilla¹, Nicole Anderson¹, Joan Wither¹, Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…
Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Francis Lao², Rahul Chanchlani¹, Anastasia Gayowsky³, Sandeep Brar⁴, Elizabeth Darling⁵, Catherine Demers⁵, Tapas Mondal¹, Rulan Parekh⁶, Hsien Seow⁵ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, ³ICES McMaster, Hamilton, ON, Canada, ⁴University of California, San Fransisco, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…
Abstract Number: 1788 • ACR Convergence 2020
Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
Andrew Kwan¹, Joan Wither², Juan Pablo Diaz-Martinez², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan², Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Dennisse Bonilla², Nicole Anderson², Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto, Department of Medicine, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is among the earliest and the most prevalent manifestations of SLE. Previous studies have demonstrated that the increased levels of interferon…
Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Erik Anderson¹, Joanna Fishbein², Joseph Hong², Julien Roeser³, Richard Furie⁴, Cynthia Aranow², Bruce Volpe², Betty Diamond⁵ and Meggan Mackay⁶, ¹Feinstein Institutes for Medical Research, New York, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Northwell Health, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 1819 • ACR Convergence 2020
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Michelle Barraclough¹, Shane McKie², Benjamin Parker¹, Alan Jackson³, Rebecca Elliott⁴ and Ian Bruce⁵, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, ⁴Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is very prevalent in SLE and significantly affects quality of life. Altered functional brain mechanisms are associated with CD in SLE.…
Abstract Number: 0026 • ACR Convergence 2020
A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
Valerie Aloush¹, Chen Yaalon², Sheer Raev², Noy Sobol², Jacob Ablin¹, Ran Shorer³ and Odelia Elkana², ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Academic College Tel Aviv Jaffa, Tel Aviv, Israel, ³Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: In a previous study, we showed that the subjective item assessing cognitive impairment (SSS-Cog) for fibromyalgia (FM) did not correlate with objective cognitive measures.…
Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
Sara Ganhão ¹, Mariana Rodrigues², Beatriz Silva ¹, Francisca Aguiar ¹, Margarida Figueiredo-Braga ¹ and Iva Brito ¹, ¹Centro Hospitalar de São João, Oporto, Portugal, ²Porto, Portugal
Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].